CABA
Price
$1.42
Change
-$0.01 (-0.70%)
Updated
Nov 3 closing price
Capitalization
240.75M
6 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.60
Change
+$0.03 (+1.17%)
Updated
Nov 3 closing price
Capitalization
399.31M
6 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs EDIT

CABA vs EDIT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CABA vs. EDIT commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Buy and EDIT is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CABA with price predictions
Nov 02, 2026

CABA in +8.94% Uptrend, advancing for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CABA advanced for three days, in 218 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Oscillator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.

CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CABA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.143) is normal, around the industry mean (3.104). P/E Ratio (-1.029) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for EDIT with price predictions
Nov 02, 2026

EDIT in +22.92% Uptrend, rising for three consecutive days on October 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where EDIT advanced for three days, in 180 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EDIT as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for EDIT just turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 38 of 48 cases over the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

EDIT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.793) is normal, around the industry mean (3.104). P/E Ratio (-3.939) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
CABA vs EDIT: Fundamental Ratings
CABA
EDIT
OUTLOOK RATING
1..100
585
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
8555
P/E GROWTH RATING
1..100
1031
SEASONALITY SCORE
1..100
3190

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (52) in the null industry is in the same range as EDIT (55) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

CABA's SMR Rating (98) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (55) in the Biotechnology industry is in the same range as CABA (85) in the null industry. This means that EDIT’s stock grew similarly to CABA’s over the last 12 months.

CABA's P/E Growth Rating (10) in the null industry is in the same range as EDIT (31) in the Biotechnology industry. This means that CABA’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CABAEDIT
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
88%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (CABA: $1.43 vs. EDIT: $2.57)
Brand notoriety: CABA and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 115% vs. EDIT: 41%
Market capitalization -- CABA: $240.75M vs. EDIT: $399.31M
CABA [@Biotechnology] is valued at $240.75M. EDIT’s [@Biotechnology] market capitalization is $399.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green while EDIT’s FA Score has 1 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 3 bullish TA indicator(s).

  • CABA’s TA Score: 5 bullish, 3 bearish.
  • EDIT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CABA is a better buy in the short-term than EDIT.

Price Growth

CABA (@Biotechnology) experienced а +5.93% price change this week, while EDIT (@Biotechnology) price change was +7.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.

Reported Earning Dates

CABA is expected to report earnings on Nov 09, 2026.

EDIT is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (-2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CABA
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XAPR38.57-0.06
-0.16%
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - April (XAPR)
FISR24.85-0.10
-0.40%
State Street Fixed Income Sector Rotation ETF (FISR)
FBCG57.56-0.84
-1.44%
Fidelity Blue Chip Growth ETF (FBCG)
ADPV43.19-0.82
-1.86%
Adaptiv Select ETF (ADPV)
PANG28.87-2.50
-7.97%
Leverage Shares 2X Long PANW Daily ETF (PANG)